No Cover Image

Journal article 268 views 21 downloads

Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study

David M. Williams Orcid Logo, Barbara-Alex Alberts, Asem Sharaf, Giselle Sharaf, Steve Bain Orcid Logo, Atul Kalhan, Thinzar Min

Diabetes Therapy, Volume: 15, Pages: 1639 - 1646

Swansea University Authors: Steve Bain Orcid Logo, Thinzar Min

  • 66445.pdf

    PDF | Version of Record

    This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

    Download (463.44KB)

Check full text

DOI (Published version): 10.1007/s13300-024-01590-x

Abstract

Introduction: Oral semaglutide improves cardiovascular risk factors in people with type 2 diabetes (T2D) in clinical trials, though real-world evidence is limited. We aimed to determine the real-world impact of oral semaglutide on routinely collected clinical data in our practice. Methods: People wi...

Full description

Published in: Diabetes Therapy
ISSN: 1869-6953 1869-6961
Published: Springer Science and Business Media LLC 2024
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa66445
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2024-05-15T12:55:38Z
last_indexed 2024-05-15T12:55:38Z
id cronfa66445
recordtype SURis
fullrecord <?xml version="1.0" encoding="utf-8"?><rfc1807 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><bib-version>v2</bib-version><id>66445</id><entry>2024-05-15</entry><title>Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>27cba511a4800fefddb6885ffffdb8b2</sid><firstname>Thinzar</firstname><surname>Min</surname><name>Thinzar Min</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2024-05-15</date><deptcode>MEDS</deptcode><abstract>Introduction: Oral semaglutide improves cardiovascular risk factors in people with type 2 diabetes (T2D) in clinical trials, though real-world evidence is limited. We aimed to determine the real-world impact of oral semaglutide on routinely collected clinical data in our practice. Methods: People with T2D initiated on oral semaglutide in secondary care diabetes clinics at two hospital sites in Wales (United Kingdom) were included. Data were collected on reasons for oral semaglutide initiation and changes in bodyweight, blood pressure, glycemic control, and lipid profiles over follow-up at 3–6 months, and at 6–12 months. Data were collected to determine the safety of oral semaglutide. Results: Seventy-six patients were included, with a median age 59.3 [51.4–67.6] years, and 38 (50.0%) patients were female. The most common reasons for oral semaglutide were need for weight loss and improved glycemia (69.8%), and improved glycemia alone (25.0%). Oral semaglutide associated with significantly reduced bodyweight (− 3.3 kg), body mass index (BMI) (– 0.9 kg/m2), glycated hemoglobin (HbA1c) (− 11 mmol/mol), and total cholesterol (− 0.4 mmol/l) by 3–6 months follow-up. At 6–12 months, there was a significant reduction in systolic blood pressure (− 7.0 mmHg), in addition to sustained reductions in other metabolic parameters. By 12 months, 18 (23.6%) patients had discontinued the drug, largely resulting from gastrointestinal disturbance, but there were no serious events in this cohort. Conclusions: Oral semaglutide was effective in improving cardiovascular risk factors in this real-world population living with T2D, and no serious events were identified related to oral semaglutide in this patient group.</abstract><type>Journal Article</type><journal>Diabetes Therapy</journal><volume>15</volume><journalNumber/><paginationStart>1639</paginationStart><paginationEnd>1646</paginationEnd><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1869-6953</issnPrint><issnElectronic>1869-6961</issnElectronic><keywords>Semaglutide; Glucagon-like peptide-1 receptor analogues; GLP-1; Type 2 diabetes; Weight loss; Real world</keywords><publishedDay>1</publishedDay><publishedMonth>7</publishedMonth><publishedYear>2024</publishedYear><publishedDate>2024-07-01</publishedDate><doi>10.1007/s13300-024-01590-x</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders>No funding was received for the preparation or publication of this manuscript.</funders><projectreference/><lastEdited>2024-10-29T11:35:39.0468766</lastEdited><Created>2024-05-15T13:54:14.9075142</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>David M.</firstname><surname>Williams</surname><orcid>0000-0001-9206-5837</orcid><order>1</order></author><author><firstname>Barbara-Alex</firstname><surname>Alberts</surname><order>2</order></author><author><firstname>Asem</firstname><surname>Sharaf</surname><order>3</order></author><author><firstname>Giselle</firstname><surname>Sharaf</surname><order>4</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>5</order></author><author><firstname>Atul</firstname><surname>Kalhan</surname><order>6</order></author><author><firstname>Thinzar</firstname><surname>Min</surname><order>7</order></author></authors><documents><document><filename>66445__30577__3062547a557b4c59ae61d726f60779f0.pdf</filename><originalFilename>66445.pdf</originalFilename><uploaded>2024-06-07T15:28:27.8966166</uploaded><type>Output</type><contentLength>474563</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling v2 66445 2024-05-15 Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 27cba511a4800fefddb6885ffffdb8b2 Thinzar Min Thinzar Min true false 2024-05-15 MEDS Introduction: Oral semaglutide improves cardiovascular risk factors in people with type 2 diabetes (T2D) in clinical trials, though real-world evidence is limited. We aimed to determine the real-world impact of oral semaglutide on routinely collected clinical data in our practice. Methods: People with T2D initiated on oral semaglutide in secondary care diabetes clinics at two hospital sites in Wales (United Kingdom) were included. Data were collected on reasons for oral semaglutide initiation and changes in bodyweight, blood pressure, glycemic control, and lipid profiles over follow-up at 3–6 months, and at 6–12 months. Data were collected to determine the safety of oral semaglutide. Results: Seventy-six patients were included, with a median age 59.3 [51.4–67.6] years, and 38 (50.0%) patients were female. The most common reasons for oral semaglutide were need for weight loss and improved glycemia (69.8%), and improved glycemia alone (25.0%). Oral semaglutide associated with significantly reduced bodyweight (− 3.3 kg), body mass index (BMI) (– 0.9 kg/m2), glycated hemoglobin (HbA1c) (− 11 mmol/mol), and total cholesterol (− 0.4 mmol/l) by 3–6 months follow-up. At 6–12 months, there was a significant reduction in systolic blood pressure (− 7.0 mmHg), in addition to sustained reductions in other metabolic parameters. By 12 months, 18 (23.6%) patients had discontinued the drug, largely resulting from gastrointestinal disturbance, but there were no serious events in this cohort. Conclusions: Oral semaglutide was effective in improving cardiovascular risk factors in this real-world population living with T2D, and no serious events were identified related to oral semaglutide in this patient group. Journal Article Diabetes Therapy 15 1639 1646 Springer Science and Business Media LLC 1869-6953 1869-6961 Semaglutide; Glucagon-like peptide-1 receptor analogues; GLP-1; Type 2 diabetes; Weight loss; Real world 1 7 2024 2024-07-01 10.1007/s13300-024-01590-x COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University Another institution paid the OA fee No funding was received for the preparation or publication of this manuscript. 2024-10-29T11:35:39.0468766 2024-05-15T13:54:14.9075142 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science David M. Williams 0000-0001-9206-5837 1 Barbara-Alex Alberts 2 Asem Sharaf 3 Giselle Sharaf 4 Steve Bain 0000-0001-8519-4964 5 Atul Kalhan 6 Thinzar Min 7 66445__30577__3062547a557b4c59ae61d726f60779f0.pdf 66445.pdf 2024-06-07T15:28:27.8966166 Output 474563 application/pdf Version of Record true This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. true eng http://creativecommons.org/licenses/by/4.0/
title Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study
spellingShingle Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study
Steve Bain
Thinzar Min
title_short Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study
title_full Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study
title_fullStr Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study
title_full_unstemmed Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study
title_sort Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
27cba511a4800fefddb6885ffffdb8b2
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
27cba511a4800fefddb6885ffffdb8b2_***_Thinzar Min
author Steve Bain
Thinzar Min
author2 David M. Williams
Barbara-Alex Alberts
Asem Sharaf
Giselle Sharaf
Steve Bain
Atul Kalhan
Thinzar Min
format Journal article
container_title Diabetes Therapy
container_volume 15
container_start_page 1639
publishDate 2024
institution Swansea University
issn 1869-6953
1869-6961
doi_str_mv 10.1007/s13300-024-01590-x
publisher Springer Science and Business Media LLC
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science
document_store_str 1
active_str 0
description Introduction: Oral semaglutide improves cardiovascular risk factors in people with type 2 diabetes (T2D) in clinical trials, though real-world evidence is limited. We aimed to determine the real-world impact of oral semaglutide on routinely collected clinical data in our practice. Methods: People with T2D initiated on oral semaglutide in secondary care diabetes clinics at two hospital sites in Wales (United Kingdom) were included. Data were collected on reasons for oral semaglutide initiation and changes in bodyweight, blood pressure, glycemic control, and lipid profiles over follow-up at 3–6 months, and at 6–12 months. Data were collected to determine the safety of oral semaglutide. Results: Seventy-six patients were included, with a median age 59.3 [51.4–67.6] years, and 38 (50.0%) patients were female. The most common reasons for oral semaglutide were need for weight loss and improved glycemia (69.8%), and improved glycemia alone (25.0%). Oral semaglutide associated with significantly reduced bodyweight (− 3.3 kg), body mass index (BMI) (– 0.9 kg/m2), glycated hemoglobin (HbA1c) (− 11 mmol/mol), and total cholesterol (− 0.4 mmol/l) by 3–6 months follow-up. At 6–12 months, there was a significant reduction in systolic blood pressure (− 7.0 mmHg), in addition to sustained reductions in other metabolic parameters. By 12 months, 18 (23.6%) patients had discontinued the drug, largely resulting from gastrointestinal disturbance, but there were no serious events in this cohort. Conclusions: Oral semaglutide was effective in improving cardiovascular risk factors in this real-world population living with T2D, and no serious events were identified related to oral semaglutide in this patient group.
published_date 2024-07-01T11:35:37Z
_version_ 1814248017418518528
score 11.037581

Similar Items